clock.bio

Executive Summary

clock.bio is a London-based biotechnology company pioneering the decoding of the rejuvenation genome—the complete set of genes enabling cells to reverse aging. By leveraging proprietary AI and high-throughput screening technologies, the company identifies genetic interventions that can restore youthful cellular function across multiple organs. Its initial focus on skin rejuvenation topicals and nutraceuticals is a strategic choice to generate rapid human data, demonstrate measurable reductions in biological age, and validate the broader platform before advancing into systemic therapies. Founded in 2021, clock.bio aims to translate these insights into real solutions that extend healthspan and improve quality of life.

Upcoming Catalysts (preview)

• Q4 2026Release of Phase I skin rejuvenation topical human biomarker data70% success
• Q2 2027Launch of first nutraceutical product targeting biological age reversal60% success
• Q4 2026Partnership with large consumer health company for co-development50% success